Table 2.

Univariate and Multivariate analysis according to cancer status in Validation1 and 2 cohorts

	Validation cohort 1				Validation cohort 2
Variables	Univariate		Multivariate		Univariate		Multivariate
	Odds ratio (CI)	p	Odds ratio (CI)	p	Odds ratio (CI)	p	Odds ratio (CI)	p
AGE	1.06(1.00–1.11)	.036	1.04(0.93–1.17)	.47	1.05(.99–1.11)	.68
PSA	.97(0.87–1.07)	.54			1.05(1.00–1.11)	.52
miR-26b-5p	.0001(.00–.002)	.0001	.0001(.00–.48)	.0001	.11(.001–.109)	<.0001	.011(.001–.11)	.0001
miR-30c	.98(0.95–1.01)	.14			.984(.96–1.101)	.27
miR-21-5p	.99(0.99–1.00)	.21			.99(.99–1.00)	.29
miR-98-5p	.77(0.54–1.10)	.160			.68(.43–1.09)	.11
miR-4732-3p	6.60(2.46–17.37)	.0001	1.82(.55–6.04)	.33	1.53(1.01–2.33)	.04	.98(0.59–1.69)	.94
Let7a-5p	.99(.98–1.00)	.117			.99(.97–1.00)	.16

Abbreviations CI, Confident Interval, p p value, PSA Prostate Specific Antigen. Data are presented as odds ratio (CI). Empty cells correspond to variables that were not measured. Baseline variables that achieved a level of significance of p < .05 in the univariate analysis were entered into multivariate models